Onco Actu du 16 novembre 2016

	3.1 Tabac
Stop smoking services under threat as budgets are cut [Cancer Research UK] Cancer Research UK is calling on the public and local councillors to help protect crucial Stop Smoking Services and mass media quit smoking campaigns by urging Westminster to solve the public health funding crisis.
Tobacco Deal Needs Smoke and Mirrors [Bloomberg] The plunge in tobacco share prices suggest investors are more worried about the end of an eight-year period of out-performance for tobacco stocks than they are excited about possible corporate tax cuts.
	4.2 Dép., diag. & prono. - Génome
One thousand cancer patients have gene testing through efficient, affordable new process [Institute of Cancer Research] The Royal Marsden now offers tests to three times as many patients a year as it used to. The new pathway is also much faster, with test results received within four weeks compared with 20 weeks in the old system.
The flip side of personal genomics: When a mutation doesn't spell disease [Nature] Researchers worry about misinforming people about the risk of disease.
	5. Traitements
‘Cough virus’ kills liver cancer cells — and the hepatitis virus that causes them [Institute of Cancer Research] The team who conducted the research at the University of Leeds found that reovirus was successful in treating both liver cancer cells grown in the laboratory and those taken directly from patients undergoing surgery. Their study is published in the journal Gut.
CRISPR gene-editing tested in a person for the first time [Nature] "I think this is going to trigger ‘Sputnik 2.0’, a biomedical duel on progress between China and the United States, which is important since competition usually improves the end product,” Carl June says.
	5.12 Immunothérapies
Roche harnesses a network of academic I/O researchers in $100M global collaborative [EndPoints] By aggregating and sharing data, Roche believes the collective research IQ of the 21 centers — dubbed imCORE; the immunotherapy Centers of Research Excellence Network — will go a long way to accelerating work on new programs that will find better ways to concentrate an immune system attack on cancer cells.
The Parker Institute aims to speed up cancer R&D, carving out duplicate IRBs at top centers [EndPoints] The Parker Institute for Cancer Immunotherapy has brought its 6 top centers together to support a simple initiative designed to shave months off the clinical trial process. Instead of each fielding their own IRB — institutional review board — they’ve agreed to designate one that will work for the entire network for multi-center studies.
	5.2 Pharma
Erytech pulls ALL filing after CHMP demands more data [FierceBiotech] CHMP has made further requests relating to an immunogenicity assay and the pharmacodynamic effects of the drug. Generating these data will take Erytech longer than is provided under the European Medicines Agency timelines, forcing it to pull the application it filed in September 2015.
	5.3 Traitements - FDA, EMA, NICE...
FDA Questions Need for Looser Off-Label Promotion Restrictions [RAPS In his opening remarks, FDA Commissioner Robert Califf acknowledged that there might be room for more flexibility regarding the information that companies can communicate off-label, though he cautioned that the issues that must be resolved in order to do so are "numerous and complex."
The European Commission launches a public consultation on the Paediatric Regulation [EMA] The feedback received will form an integral part of the Commission's final report assessing the impact of the Paediatric Regulation on public health and the pharmaceutical industry, which is expected to be published in 2017.
	5.4 Traitements - Economie
Britain 'spends twenty times as much on junk food as on cancer drugs' [The Telegraph] A report by University College London calls for the introduction of a “more humane” approach to drug funding, warning that spending in the UK is lagging badly behind that of other countries.
	5.7 SABCS
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer [Novartis] Most notable among Novartis' clinical data to be featured at the two meetings are from the ongoing registrational trials for investigational CTL019 and LEE011(ribociclib).
	6. Lutte contre les cancers
Researching Cancer in the LGBT Community [AACR] A variety of factors could increase cancer risk in LGBT people. Gay men are at an elevated risk of viral infections like HIV and HPV that raise susceptibility to certain cancers, such as Hodgkin lymphoma, anal cancer, and oral cancer. In lesbian and bisexual women, a relatively low rate of childbearing and breastfeeding could increase breast cancer risk. And nearly one in four lesbian, gay, and bisexual adults smoke, compared to one in six heterosexual adults.
	6.1 Observation
Breast cancer 'more often advanced' in black women [BBC News] Black women in England are almost twice as likely to be diagnosed with advanced breast cancer as white women, according to a new analysis by Cancer Research UK and Public Health England.
Past depression tied to worse breast cancer survival odds [Reuters] In the study of more than 45,000 women with early-stage breast malignancies, 13 percent of patients previously treated with antidepressants died within five years of their cancer diagnosis, compared with 11 percent of women who hadn’t ever taken medication for depression.
	6.10.1 Politiques (USA)
Donald Trump Can't Prop Up Drug Prices [Bloomberg] It's tough to read the bird entrails on a future President who radically alters policy positions on a regular basis. But even if Trump ends up being a pharma friend, it's worth remembering that some of the biggest pricing pressures the industry faces come from the private sector, and they're growing in severity.
	6.9 Controverses
Precision Medicine and Uncertainty [Science-Based Medicine] In the early days of genome analysis, the promise seemed infinite. We hoped to pinpoint the genes responsible for every illness. We hoped to find certainty and solutions. We are not there yet, and we are beginning to question whether we ever will be.